Cladribine and Filgrastim-aafi Intravenous, Subcutaneous
Determining the interaction of Cladribine and Filgrastim-aafi Intravenous, Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids. MANAGEMENT: Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
Professional:GENERALLY AVOID: The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: n.a.
Generic Name: filgrastim
Brand name: Neupogen, Neupogen SingleJect, Nivestym, Zarxio
Synonyms: Filgrastim-aafi
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine-Filgrastim-sndz
- Cladribine-Finacea
- Cladribine-Finacea (Azelaic Acid Foam)
- Cladribine-Finacea (Azelaic Acid Gel)
- Cladribine-Finacea Foam
- Cladribine-Finacea Plus
- Filgrastim-aafi Intravenous, Subcutaneous-Cladribine (oral)
- Filgrastim-aafi Intravenous, Subcutaneous-Cladribine injection
- Filgrastim-aafi Intravenous, Subcutaneous-Cladribine Intravenous
- Filgrastim-aafi Intravenous, Subcutaneous-Cladribine Tablets
- Filgrastim-aafi Intravenous, Subcutaneous-Claforan
- Filgrastim-aafi Intravenous, Subcutaneous-Claforan in D5W